Neuberg Diagnostics to invest Rs 300 cr for expansion

Mumbai: Neuberg Diagnostics, an alliance of five leading pathology laboratories from India, South Africa and the UAE, is planning to invest Rs 300 crore in India, the Middle East and Africa as part of its expansion plans.

“We are looking at investing another Rs 300 crore for expansion plans in the coming years, which will be funded through internal accruals,” Neuberg Diagnostics chairman GSK Velu told here.

The company having focus on new generation technologies in the diagnostics space, according to Velu has already invested Rs 450 crore in acquiring laboratories in India and abroad and upgrading them.

Neuberg at present has 50 labs and 500 centres in the south and west India, and plans to increase the total count to 150 labs and 1,000 centres in the next three years.

“We will have three world class global reference laboratories located in Bengaluru, Ahmedabad, and Durban (South Africa) carrying out advanced range of testing using new generation in vitro diagnostics techniques,” he said.

The company sees faster growth in African markets and plans to enter into Kenya, Uganda, Nigeria, Tanzania and Ethiopian markets.

According to Velu, new generation technologies like genomics, metabolomics and proteomics that provide accurate diagnosis and also combination diagnostics, where hospitals, pharma companies and pathologists work together, is the future of the diagnostics industry.

“India is lagging behind in terms of technology and we wants to focus in those areas,” he said.

An alliance of five top laboratories like Anand Diagnostic Laboratory, Supratech Micropath, Ehrlich lab, Global labs and Minerva Labs, the company plans to have three infrastructure models global centre of excellence, regional reference centres and satellite centres.

It also wants to establish research centres in the US and European markets, to get access to latest technologies and bring it to India, according to Velu.

“Talks are on with some universities and small labs in the regions,” he said.

The company, which is growing at a compounded annual growth rate of 15 per cent, clocked an consolidated revenue of Rs 400 crore last year and hopes to cross Rs 1,000-crore mark by 2021-22.

  • Related Posts

    A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

    Healthy Heart is a Misnomer until underpinned by Regular Screening Bangaluru/ New Delhi: Of late, heart health has become kind of a veritable conundrum. We were never so unsure of…

    Health Ministry Unveils Thalassemia Awareness Posters to Promote Early Screening

    The aim is to encourage adolescents and antenatal women to undergo timely thalassemia screening New Delhi: The Ministry of Health and Family Welfare unveiled two awareness posters on thalassemia screening…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’